Clinical Trial Update: Netupitant and Palonosetron Hydrochloride in Preventing Chronic Nausea and Vomiting in Patients With Cancer [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/Phase 3 trial evaluating netupitant and palonosetron hydrochloride for prevention of chronic nausea and vomiting in patients with cancer; study complete…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Neoplasm
• Nausea and Vomiting in Cancer

Drugs mentioned

• Netupitant and Palonosetron Hydrochloride (netupitant and palonosetron)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Malignant Neoplasm, Nausea | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2023-10-17